SINGAPORE: All five new COVID-19 infections in Singapore as of noon on Wednesday (November 18th) have been reported.
No locally transmitted events were reported for the eighth consecutive day.
Three of the imported cases are work permit holders, aged 23, 30 and 33, who arrived from Myanmar.
Another case involved a 15-year-old student cardholder who arrived from India.
The remaining case is a 70-year-old Bangladesh short-term visitor who was allowed to enter as he had already received medical treatment in Singapore and returned for further treatment, the Ministry of Health (MOH) said.
All cases were asymptomatic, the minister said, adding that they were put on notice of staying at home or isolated on arrival in Singapore.
New infections bring the number of COVID-19 cases in the country to 58,135.
Seven more cases have been removed from hospitals or community isolation facilities, bringing Singapore’s total recoveries to 58,046.
There are still 33 cases in the hospital. Most of them are stable or improving and no one is in the intensive care unit. Another 28 are isolated and cared for in community facilities.
To date, 28 have died from complications due to COVID-19 infection.
The State Department also announced that, as there have been no more cluster-related cases at ASPRI-Westlite Papan at 5 Jalan Papan for the last two incubation periods, the cluster is now closed.
He added that he monitors existing clusters for any further transmission.
More details can be found in the daily report on the situation of the Ministry of Health
Pfizer is “very close” to applying for emergency approval for the COVID-19 vaccine after collecting safety data for submission to US regulators, the company’s CEO said on Tuesday.
The pharmaceutical giant announced last week that a clinical trial at the end of the stage showed that the vaccine was more than 90% effective after the second dose.
READ: The vaccine will not be enough to stop the COVID-19 pandemic – WHO leader
Explanator: Where are we in the COVID-19 vaccine race?
On Monday, Moderna and the US National Institutes of Health announced similar preliminary results from their own trial, finding that their vaccine was almost 95% effective.
The Sinovac Biotech CoronaVac vaccine elicited a rapid immune response, but the level of antibodies produced was lower than in people who had recovered from the disease, according to preliminary test results Wednesday.
While early to mid-stage trials were not designed to evaluate the effectiveness of CoronaVac, the researchers said they could provide adequate protection, based on their experience with other vaccines and data from preclinical studies in macaques.
READ: Shot in the dark: Early effectiveness of COVID-19 vaccine explained
The head of the World Health Organization, Tedros Adhanom Ghebreyesus, welcomed “encouraging” news about the COVID-19 vaccine. However, he expressed concern about the increase in cases in many countries and insisted that complacency was not an option.
PRODUCTION THIS: Our comprehensive coverage of the coronavirus outbreak and its developments
Download our app or subscribe to the Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram